Andria Petersen, NP
Psychiatric/Mental Health · Sioux Falls, SDNPI 1194280156
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$960
- Supernus Pharmaceuticals, Inc.$862
- Teva Pharmaceuticals USA, Inc.$716
- Tris Pharma Inc$318
- Vanda Pharmaceuticals Inc.$251
- AbbVie$213
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,83298%
- Education$812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 59 | $960 |
| Supernus Pharmaceuticals, Inc. | 78 | $862 |
| Teva Pharmaceuticals USA, Inc. | 25 | $716 |
| Tris Pharma Inc | 12 | $318 |
| Vanda Pharmaceuticals Inc. | 13 | $251 |
| AbbVie | 16 | $213 |
| Corium, LLC | 18 | $193 |
| Alkermes, Inc. | 10 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $170 |
| Lundbeck LLC | 9 | $134 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $130 |
| Jazz Pharmaceuticals Inc. | 6 | $112 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| Acadia Pharmaceuticals Inc | 5 | $91 |
| Neurocrine Biosciences, Inc. | 5 | $77 |
| Merck | 5 | $70 |
| Idorsia Pharmaceuticals US Inc | 5 | $68 |
| Johnson & Johnson | 4 | $63 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Almatica Pharma LLC | 3 | $44 |
| Biogen | 2 | $44 |
| Eisai Inc. | 1 | $22 |
| Harmony Biosciences LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$264
- Dyanavel XR$124
- Quillivant$124
- Quillichew ER$124
- REXULTI$123
- Austedo XR$123
- UZEDY$122
How this compares
$4,914 in reported general payments places this provider in the 95th percentile of 77 psychiatric/mental health providers in South Dakota.
See all psychiatric/mental health providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $106,984 |
| RexultiBrexpiprazole | 35 | $58,541 |
| Aripiprazole | 107 | $12,081 |
| TrintellixVortioxetine Hydrobromide | 27 | $7,576 |
| Lisdexamfetamine Dimesylate | 32 | $6,341 |
| Methylphenidate ErMethylphenidate Hcl | 22 | $6,170 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,368 |
| Bupropion XlBupropion Hcl | 185 | $3,736 |
| Divalproex Sodium | 37 | $2,645 |
| Olanzapine | 127 | $2,139 |
| Duloxetine Hcl | 126 | $1,917 |
| Fluoxetine Hcl | 181 | $1,684 |
| Memantine Hcl | 24 | $1,396 |
| Vilazodone Hcl | 20 | $1,340 |
| Lurasidone Hcl | 34 | $1,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $77 | $106,98414 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $960 | $58,54135 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $170 | $11,94539 claims |
| Almatica Pharma LLCSertraline Hcl | $44 | $1,042124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 psychiatric/mental health providers in South Dakota.
Other psychiatric/mental health in Sioux Falls
- Nichole JohnsonSioux Falls$5K
- Holly AhlersSioux Falls$4K
- Afton ArtzSioux Falls$2K
- Audrey FuksSioux Falls$2K
- Marie JamesonSioux Falls$761
- Veronica SherwoodSioux Falls$756
- Taylor RobertsSioux Falls$717
- Kaitlyn WalkerSioux Falls$574
- Hannah OttenSioux Falls$376
- Garneth KuiperSioux Falls$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.